Chicago Equity Partners LLC grew its holdings in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 3.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,558 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,483 shares during the quarter. Chicago Equity Partners LLC’s holdings in ANI Pharmaceuticals were worth $2,237,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ANIP. Piedmont Investment Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $140,000. Truvestments Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $152,000. Crossmark Global Holdings Inc. bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $235,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $267,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $272,000. 61.10% of the stock is owned by institutional investors.

ANIP opened at $52.66 on Friday. ANI Pharmaceuticals Inc has a twelve month low of $48.40 and a twelve month high of $74.70. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.34 and a quick ratio of 2.89. The stock has a market cap of $639.13 million, a P/E ratio of 12.25 and a beta of 2.64.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.12. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. The business had revenue of $50.70 million during the quarter, compared to analysts’ expectations of $50.97 million. During the same quarter in the prior year, the business posted $1.11 earnings per share. ANI Pharmaceuticals’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts anticipate that ANI Pharmaceuticals Inc will post 4.49 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on ANIP shares. BidaskClub cut shares of ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 19th. Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 3rd. ValuEngine raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, Canaccord Genuity set a $75.00 price objective on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $71.00.

TRADEMARK VIOLATION NOTICE: “Chicago Equity Partners LLC Acquires 1,483 Shares of ANI Pharmaceuticals Inc (ANIP)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://theolympiareport.com/2018/11/11/chicago-equity-partners-llc-acquires-1483-shares-of-ani-pharmaceuticals-inc-anip.html.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Recommended Story: Preferred Stock

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.